Does nebivolol prevent contrast-induced nephropathy in humans
Clinical Cardiology, 04/26/2012Gunebakmaz O et al.
Pretreatment with nebivolol is protective against nephrotoxic effects of contrast media.
The present study enrolled 120 patients scheduled for coronary angiography and ventriculography.
All patients were hydrated with intravenous isotonic saline.
The patients in group I received 600 mg N–acetylcysteine every 12 hours for 4 days.
The patients in group II received 5 mg nebivolol every 24 hours for 4 days.
The patients in group III were only hydrated.
The primary endpoint was the occurrence of CIN.
The secondary endpoint was the change in serum creatinine (Cr) levels at 2 days and 5 days after the contrast exposure.
Nine (22.5%) patients in group I developed CIN, as did 8 patients (20.0%) in group II and 11 patients (27.5%) in group III (P = 0.72).
Changes in mean Cr level from baseline to day 2 were not statistically significant in all groups.
However, authors detected a statistically significant increase in mean Cr levels at day 5 compared with baseline levels in group I and group III (from 1.42 ± 0.13 to 1.52 ± 0.26, p2 = 0.02; and from 1.43 ± 0.14 to 1.55 ± 0.30, p2 = 0.01, respectively).
Although an increase was detected in mean Cr level from baseline to the 5–day Cr level in group II, this did not reach statistical significance (from 1.40 ± 0.12 to 1.48 ± 0.23, P = 0.06).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.